Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DOXIL (LIPOSOMAL) vs AFATINIB
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Doxorubicin intercalates between DNA base pairs, inhibits topoisomerase II, and generates free radicals, leading to DNA damage and cell death. Liposomal encapsulation prolongs circulation time and alters biodistribution.
Afatinib is an irreversible, covalent-binding inhibitor of the Erb B family of tyrosine kinases, including EGFR (Erb B1), HER2 (Erb B2), Erb B3, and Erb B4. It blocks downstream signaling pathways such as PI3K/AKT and MAPK, leading to inhibition of tumor cell proliferation and survival.
Ovarian cancer after failure of platinum-based chemotherapy,AIDS-related Kaposi sarcoma,Multiple myeloma in combination with bortezomib
First-line treatment of metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations,Treatment of metastatic squamous NSCLC progressing after platinum-based chemotherapy,Off-label: Use in other EGFR-mutant cancers (e.g., head and neck cancer, colorectal cancer) with specific mutations
Doxorubicin HCl liposome injection 20 mg/m2 intravenously over 1 hour every 4 weeks.
40 mg orally once daily, continuously.
Terminal half-life is approximately 30–40 hours, prolonging drug exposure and allowing every-4-week dosing.
Terminal half-life is approximately 37 hours; supports once-daily dosing with steady-state achieved within 8 days.
Primarily hepatically metabolized by aldo-keto reductases to doxorubicinol (active metabolite); also metabolized by cytochrome P450 (minor) and glycosidases.
Primarily metabolized by CYP3A4 and to a lesser extent by CYP3A4-independent pathways including flavin-containing monooxygenase (FMO). Excretion mainly via feces (85%) and urine (4%) as unchanged drug and metabolites.
Primarily hepatic metabolism and biliary excretion; urinary excretion accounts for <10% of the administered dose as unchanged drug.
Primarily fecal (85%) as unchanged drug and metabolites; renal excretion accounts for <4% of the dose.
Approximately 90% bound to plasma proteins, primarily albumin.
Approximately 95% bound to plasma proteins, primarily to albumin.
Vd approximately 2.8 L/m² (not directly L/kg; low Vd indicates predominant plasma compartment retention).
Volume of distribution is approximately 2300 L (about 33 L/kg for a 70 kg individual), indicating extensive tissue distribution.
Only intravenous administration; oral bioavailability is negligible.
Oral bioavailability is approximately 92% relative to an oral solution; food reduces exposure, so take on an empty stomach.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not recommended in severe renal impairment (Cr Cl <30 m L/min) due to lack of data.
No starting dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not recommended for severe renal impairment (Cr Cl <30 m L/min) due to safety concerns.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: not recommended.
Child-Pugh A: 40 mg once daily. Child-Pugh B: Reduce dose to 30 mg once daily. Child-Pugh C: Not recommended due to lack of data.
Safety and efficacy not established in pediatric patients.
Safety and efficacy not established in pediatric patients; no specific dosing recommendations.
No specific dose adjustment recommended, but monitor for increased toxicity (e.g., cardiotoxicity, myelosuppression) due to age-related organ function decline.
No specific dose adjustment recommended based on age alone; monitor renal function and tolerability, as elderly patients may have decreased renal function or comorbidities.
Cardiotoxicity: risk of myocardial damage, including acute left ventricular failure. Myelosuppression: severe, dose-limiting. Hepatic impairment: requires dose reduction. Infusion reactions: may be severe or life-threatening. Must be administered by physician experienced in cancer chemotherapy.
None.
Cardiotoxicity (cumulative dose-dependent, monitor LVEF), myelosuppression (neutropenia, thrombocytopenia), infusion reactions (premedicate), hand-foot syndrome (palmar-plantar erythrodysesthesia), secondary malignancies, extravasation necrosis, hepatic impairment (dose adjustment), immunosuppression, embryo-fetal toxicity.
Severe diarrhea (including dehydration and acute kidney injury),Interstitial lung disease (ILD)/pneumonitis,Severe hepatotoxicity (elevated liver enzymes, hepatitis),Left ventricular dysfunction (assess LVEF at baseline and during treatment),Severe bullous, blistering, and exfoliative skin reactions (e.g., Stevens-Johnson syndrome),Gastrointestinal perforation,Ocular toxicities (keratitis, conjunctivitis),Renal toxicity (proteinuria, nephrotic syndrome),Fetal harm (embryo-fetal toxicity),Drug interactions with CYP3A4 inducers or inhibitors
Absolute: history of hypersensitivity to doxorubicin or other anthracyclines. Relative: severe hepatic impairment, severe myelosuppression, pre-existing cardiomyopathy, prior treatment with maximum cumulative doses of anthracyclines (e.g., doxorubicin >550 mg/m², liposomal doxorubicin >900 mg/m²).
None reported,Relative contraindications: pre-existing severe hepatic impairment, severe renal impairment, pregnancy, and breastfeeding
No specific food interactions reported. Avoid grapefruit juice per general chemotherapy precautions. Maintain adequate oral hygiene; avoid spicy or acidic foods during mucositis.
Take on an empty stomach (at least 1 hour before or 2 hours after food). Avoid grapefruit, grapefruit juice, and Seville oranges as they may alter drug metabolism. High-fat meals reduce absorption.
Doxorubicin hydrochloride liposome injection (DOXIL) is classified as Pregnancy Category D. There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans. Potential benefits may warrant use of the drug in pregnant women despite potential risks. First trimester: High risk of teratogenicity including major malformations (e.g., cardiovascular, neural tube defects). Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and neonatal myelosuppression. Use only if clearly needed and no safer alternative.
Afatinib is classified as Pregnancy Category D. First trimester exposure is associated with increased risk of major congenital malformations, including cardiac, skeletal, and neural tube defects based on animal studies showing embryotoxicity and teratogenicity at doses below human exposure. Second and third trimester exposure may cause fetal growth restriction, oligohydramnios, and impaired renal function due to inhibition of EGFR signaling critical for fetal development.
Doxorubicin is excreted in human milk. The milk-to-plasma (M/P) ratio for doxorubicin is approximately 0.5 to 2.0 based on limited data. Because of the potential for serious adverse reactions in nursing infants from doxorubicin (e.g., myelosuppression, cardiotoxicity), discontinue breastfeeding during and for at least 3 months after the last dose of DOXIL.
No human data on afatinib excretion in breast milk; however, animal studies indicate drug presence in milk. M/P ratio is unknown. Due to potential for serious adverse effects in breastfed infants, breastfeeding is contraindicated during therapy and for at least 2 weeks after the last dose.
Pharmacokinetic data in pregnancy are limited; however, physiological changes (e.g., increased plasma volume, hepatic clearance) may alter doxorubicin exposure. No specific dose adjustment guidelines exist. Use the standard dose based on body surface area (BSA) while closely monitoring for toxicity. Consider dose reduction if severe myelosuppression or hepatic impairment occurs. Avoid use in the first trimester if possible.
No specific dosing guidelines for pregnancy. Pharmacokinetic changes (increased volume of distribution, altered metabolism) may occur but studies have not established dose adjustments. The drug should be avoided in pregnancy unless benefit outweighs risk; if used, consider therapeutic drug monitoring if available.
Monitor for infusion reactions; premedicate with dexamethasone and antihistamines. Palmar-plantar erythrodysesthesia (hand-foot syndrome) may require dose delay/reduction. Cumulative dose >550 mg/m² increases cardiotoxicity risk. Do not substitute with non-liposomal doxorubicin.
Monitor for diarrhea, which can be severe; consider loperamide and hydration. Assess for interstitial lung disease (ILD) and hepatotoxicity. Dose reduction required for severe renal impairment (Cr Cl 15–29 m L/min). For patients with EGFR exon 19 deletion or exon 21 L858R mutation, first-line use improves PFS. Avoid P-glycoprotein strong inducers (e.g., rifampin) during treatment.
Report immediately any redness, swelling, or pain on palms or soles (hand-foot syndrome).,Avoid prolonged sun exposure and use sunscreen to prevent photosensitivity.,Notify your doctor if you experience chest pain, shortness of breath, or swelling (cardiotoxicity signs).,Take anti-nausea medications as prescribed; maintain adequate hydration.,Use effective contraception during treatment and for 6 months after.
Take afatinib at least 1 hour before or 2 hours after a meal.,Do not crush, chew, or split tablets; swallow whole with water.,Seek medical help for severe or persistent diarrhea, cough, or difficulty breathing.,Avoid grapefruit and Seville oranges during treatment.,Report signs of liver problems (yellowing skin/eyes, dark urine).,Use effective contraception during and for 2 weeks after stopping therapy.,Avoid direct sunlight exposure; use sunscreen.
No interactions on record
"Afatinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, and fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), both undergo metabolism via CYP450 enzymes. Afatinib is a moderate inhibitor of CYP2D6 and may also inhibit CYP1A2 and CYP3A4, while fluvoxamine is a known inhibitor of CYP1A2 and CYP2C19. Coadministration can lead to increased fluvoxamine concentrations due to inhibition of its metabolism, potentially resulting in enhanced serotonergic effects such as serotonin syndrome, as well as increased adverse effects like nausea, dizziness, or QT prolongation."
"The combination of afatinib, a tyrosine kinase inhibitor, with pantoprazole, a proton pump inhibitor (PPI), can lead to reduced absorption of afatinib due to elevated gastric pH. Afatinib exhibits pH-dependent solubility, and higher gastric pH decreases its dissolution and bioavailability, potentially reducing its therapeutic efficacy. This interaction may result in suboptimal plasma concentrations of afatinib, increasing the risk of treatment failure in patients with non-small cell lung cancer."
"Estrone, an estrogen hormone, may induce the expression of UDP-glucuronosyltransferase (UGT) enzymes, which are involved in the glucuronidation and subsequent clearance of afatinib. This induction can lead to a decrease in afatinib serum concentrations, potentially reducing its efficacy in the treatment of non-small cell lung cancer. Clinically, this interaction may result in suboptimal therapeutic outcomes unless the afatinib dose is adjusted."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DOXIL (LIPOSOMAL) vs AFATINIB, answered by our medical review team.
DOXIL (LIPOSOMAL) is a Anthracycline Antineoplastic that works by Doxorubicin intercalates between DNA base pairs, inhibits topoisomerase II, and generates free radicals, leading to DNA damage and cell death. Liposomal encapsulation prolongs circulation time and alters biodistribution.. AFATINIB is a Tyrosine Kinase Inhibitor Antineoplastic that works by Afatinib is an irreversible, covalent-binding inhibitor of the Erb B family of tyrosine kinases, including EGFR (Erb B1), HER2 (Erb B2), Erb B3, and Erb B4. It blocks downstream signaling pathways such as PI3K/AKT and MAPK, leading to inhibition of tumor cell proliferation and survival.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DOXIL (LIPOSOMAL) and AFATINIB depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DOXIL (LIPOSOMAL) is: Doxorubicin HCl liposome injection 20 mg/m2 intravenously over 1 hour every 4 weeks.. The standard adult dose of AFATINIB is: 40 mg orally once daily, continuously.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DOXIL (LIPOSOMAL) and AFATINIB in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DOXIL (LIPOSOMAL) is classified as Category C. Doxorubicin hydrochloride liposome injection (DOXIL) is classified as Pregnancy Category D. There is positive evidence of human fetal risk based on adverse reaction data from inves. AFATINIB is classified as Category C. Afatinib is classified as Pregnancy Category D. First trimester exposure is associated with increased risk of major congenital malformations, including cardiac, skeletal, and neura. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.